NZ207793A - Preparation of oligosaccharide fractions from heparin - Google Patents

Description

New Zealand Paient Spedficaiion for Paient Number £07793 T 2 07793 . ;.cnty Dste(s): .

Complete Specification Filed: IO~. .Cc.S.6f Ctass: CiQ 5? B Bi"?. 11 Q Publication Date: .,.

P.O. Journal, Mo: .. A?S3.

M F ^ fl FM? J* ^ ;Patents Form No. 5 Number ;PATENTS ACT 1953 Dated ;COMPLETE SPECIFICATION ;Process for the preparation of oligosaccharide fractions having pharmaceutical properties by chemical degradation of heparin tfWe OPOCRIN S.p.A, a company incorporated under the laws of Italy, of Via Pacinotti, 3 Corlo, Modena, Italy do hereby declare the invention for which l?we pray that a Patent may be granted to Km/us, and the method by which it is to be performed, to be particularly described in and by the following statement: ;- 1 - (followed by page la) ;2 0779 ;- 1 a- ;The present invention refers to a chemical process for the preparation of oligosaccharide fractions having interesting biological activities starting from heparin. ;5 The invention embraces also the so obtained oligosaccharide fractions. ;It is known that oligosaccharides and oligosac charide fractions containing the same, derived from heparin, show an interesting anti Xa activity 10 of the blood, which is believed to correspond to a high antithrombotic activity associated with a relatively low anticoagulant activity. ;Such oligosaccharides and/or oligosaccharide fractions containing the same have a relati vely 15 low average molecular weight, about 5,000 Daltons. They are obtained from heparin by means of degradation processes, commonly defined as depolymeri-zation processes, having the purpose of producing fragments of molecular weights lower than 20 those of the starting heparin. Said processes are substantially of two types: enzymatic and chemical . ;The known chemical processes include the . treat ment with nitrous acid, the oxidation by means 25 of peroxides carried out both under atmospheric ;2 0779 ;- 2 - ;and higher pressure and the oxidation by means of periodates. ;S.E. Lasker in "Low molecular-weight derivative of heparin that is orally active in mice" in Adv. ;5 Exp. Med. and Biol. Vol. 52 "Heparin Structure Fun ction and Clinical implications" p. 119-130 Plenum Press N.Y. (1975) has described a process which com prises depolymerizing the heparin by incubation at 40°C for 24 hours of its aqueous solution in the 10 presence of ascorbic acid and cupric sulphate. According to the same author, it is possible and even preferred, in order to avoid the pollution of the product induced by cupric ions, to substitute the cupric sulphate with a 3% solution of hydrogen 15 peroxide. ;Nevertheless it has been experimentally found that, apart from the pollution due to the copper, the depolymerization of the heparin carried out in the presence of ascorbic acid and cupric sulpha 20 te leads to oligosaccharide fractions having an ave rage molecular weight still very high, usually high er than 9,200 Daltons. ;It is clear that in order to isolate the most in teresting fractions from this oligosaccharide mix-25 ture ie., those having an average molecular weight ranging from 4,000 to 5,000,it is necessary to carry out fractionations by means of solvents, particularly ethanol, as described by Lasker same with a consequent considerable lowering of yields of use ;2 07/ 9 ;ful product. ;Also the depolymerization carried out in the presence of ascorbic acid and a 3% solution of hydrogen peroxide (the latter in substitution of 5 the cupric sulphate) leads to oligosaccharide fractions having a high average molecular weight of about 11,500 Daltons, scarcely utilizable for the preparation, by means of fractionation of oligosaccharide fractions having the desired average 10 molecular weight. ;Also the depolymerization carried out by combining both the above cited techniques, which is carried out in the presence of ascorbic acid, cupric sulphate and a 3% solution of hydrogen peroxi 15 de, leads to fractions having an average molecular weight higher than 9,000 Daltons. The above cited combination of operative conditions (cupric sulpha te and hydrogen peroxide) is not indicated, not even suggested by Lasker in his above mentioned 20 work. Nevertheless, the depolymerization in such conditions has been considered a possible improvement of the single Lasker processes. ;By repeating experimentally the process which employ copper, it could be confirmed that they 25 lead to oligosaccharide fractions irreversibly pol^ luted by cupric ions. ;It has now surprisingly been found that it is possible to obtain directly oligosaccharide frac tions having an average molecular weight very clo ;2 ;;/ / ' i/ (J ;~X ;- 4 - ;se to the desired one by means of the process for the degradation of heparin which is the object of the present invention and which comprises incubating an aqueous solution of heparin containing from 5 5 to 20 g of heparin per liter, in the presence of 4-50 m.moles/1 of ascorbic acid, 0,4-2,5 m.moles/1 of cupric acetate and 50-300 m.moles/1 of hydrogen peroxide at a temperature of 40-50°C for 20-24 hours and maintaining the pH at a value of 7,5-8 10 by means of sodium acetate. ;The best results are obtained by incubating an aqueous solution of heparin containing 10 g of heparin per liter, in the presence of 20 m.moles/1 of ascorbic acid, of 2.25 m.moles of cupric aceta-15 te and of 180 m.moles of hydrogen peroxide at a temperature of about 50°C for 24 hours and at a pH of 7.8. ;In comparison with the known methods the process of the present invention allows to obtain oligosac 20 charide fractions having an average molecular weight which does not require any further fractionation procedure. The obtained products, furthermore, are not irreversibly polluted by residuals of cupric ions. ;25 Occasional traces of cupric compounds can ea sily be removed through dissolution in water, addition of chelating agents such as, for instance, EDTA and precipitation from suitable solvents. ;If desired, it is possible to submit the oligo ;20779 ;- 5 - ;saccharides obtained by means of the process of the present invention to purification and/or frac tionation processes, known in the art. It is there fore possible to obtain products whose biological 5 activities are further enhanced. ;Although it is possible to carry out the process of the present invention within rather wide ranges of concentrations, the best results, with reference both to the average molecular weight of the ob 10 tainable oligosaccharide fractions and to their biological properties, are achieved by operating at concentrations comprised between 5 and 10 g of heparin per liter of solution, by maintaining substantially constant the molar ratios of the va 15 rious reagents with reference to the heparin. ;In order to keep the pH suitable for carrying out the depolymerization process, different buffering agents can be used: nevertheless it has been found that the sodium acetate gives the most sati-20 sfying results. ;In fact it does not form with the cupric ions present in the solution those hardly reversible and scarcely soluble complexes which lead in turn to a pollution of the product. ;25 The mixtures of oligosaccharides obtained accor ding to the process of the present invention display a very low degree of anticoagulant activity, much lower than that displayed by the starting heparin. The anticoagulant activity of the oligo- ;207/9 3 ;- 6 - ;saccharide fractions obtained according to the process of the present invention, determined by means of the USP method (see the foot note on table 1) is only the 20-30% of the activity of the starting he-5 parin. ;The anticoagulant activity evaluated in vitro as APTT (see note as above) is reduced to 10-15% of that of the heparin. ;On the contrary the activity inhibiting the Xa 10 factor evaluated by means of the coagulometric method (see note as above) is reduced to 25-35% of that of the heparin, while, if evaluated by means of the croraogenic method (see the above note) it is reduced to the 55-60% of that of the heparin. 15 If one takes into consideration the ratio bet ween the anti Xa activity evaluated by means of the cromogenic method and the APTT activity (anti Xa cr/APTT), as well as the ratio between the anti Xa activity evaluated by means of the coagulometric 20 method and the APTT activity (anti Xa Co/APTT), it is possible to verify that, with respect to the heparin, these ratios are of about 0.6 for the anti Xa Cr/APTT, and of about 0.8 for the anti Xa Co/APTT. ;25 For the products prepared by the process of the present invention, corresponding values of about 4 and about 2 respectively are obtained. This corresponds to a percent increase of about 600% and 250%. ;The products obtained by the process of the pre ;- 7 - ;sent invention are thus able to considerably inhibit the Xa factor and, at the same time, possess a very poor anticoagulant activity. Accordingly, they are very interesting for the possible use 5 as drugs for the antithrombotic treatment practically free from the risk of hemorrages. ;The products of the present invention show an average molecular weight comprised between 3,000 and 6,000 Daltons. ;10 The following examples are given only by way of illustration, but must not be considered as a limitation of the invention itself. ;EXAMPLE 1 ;Commercial heparin having an average molecular 15 weight of 13,500 Daltons and provided with the biological properties shown in table 1, was submitted to depolymerization according to the process of the present invention. ;Grams 10 of heparin were dissolved in 700 ml of 20 an aqueous solution containing g 30 (500 m.moles) of sodium chloride and 30 g (200 m.moles) of sodium acetate tri-hydrate (CH^ COONa . 3H2O). The pH was adjusted to 7.8 by means of NaOH 2N. The resulting solution was then added under stirring 25 first with 200 ml of an aqueous solution containing 3.5 g (20 m.moles) of ascorbic acid, brought to a pH 7-7.5 by means of NaOH, and subsequently with IOO ml of an aqueous solution containing 0.45 g (2.25 m.moles) of cupric acetate monohydrate ;• • .O- "^7 T ' I ;- 8 - ;(CH COO") Cu . H20. ;Finally 15 ml of 36% hydrogen peroxide (180 m.moles) were added always under stirring. ;The pH was adjusted to 7.8 by means of concentra-5 ted NaOH and the mixture was kept at 50°C for 20 hours. ;After concentration under vacuum to half a volu me, an amount of 3%o by weight, referred to the vo lume of the mixture, of EDTA sodium salt was added, 10 the pH was brought to 6.5-7 and the product was pre cipitated by addition of 2 volumes of methanol. ;The product was purified by repeating two times the precipitation with methanol. ;The yield by weight of oligosaccharides having 15 an average molecular weight of 4,500 Daltons was ;87.5%. The biological characteristics are shown in table 1. ;EXAMPLE 2 ;The depolymerization process described in the pre 20 ceding example was repeated by operating with identi cal techniques and with the same quantity of starting material and reagents. ;The only variations were the incubation tempera ture, 40°C instead of 50°C, and the time, 24 hours 25 instead of 20. ;The yield in oligosaccharides was 88% by weight and their average molecular weight was 3,946 Daltons. The biological activities are shown in Table 1. ;2 077 9 ;- 9 - ;EXAMPLE 3 ;The preceding example was repeated in identical manner, reducing the concentration of the reagents to 1/5, but keeping constant the ratios between the 5 single reactants. ;The yield was 90% and the average molecular weight was 5,590. ;EXAMPLE 4 ;The depolymerization process described in the pre 10 ceding example was repeated, but operating at a higher concentration. ;25 G of heparin were treated as described in the preceding examples with 50 m.moles of ascorbic acid, 6.25 m.moles of cupric acetate and 450 m.moles of 15 hydrogen peroxide. ;The reaction mixture, the volume of which was 1 liter, contained also 100 m.moles of sodium chloride ;The yield in oligosaccharide fractions was 75% by weight and their average molecular weight was 20 5,986. ;By comparing the results of examples 2, 3 and 4 it can be observed that, surprisingly, the best results are obtained when the heparin concentration is about 10 g/1, though the molar ratios between the 25 reagents and between these ones and the heparin remain substantially the same. ;EXAMPLE 5 ;In order to put into evidence the differences between the methods described in the literature and ;2 077 ;- 10 - ;the process of the present invention, the process described by S. Lasker was repeated. ;a) Depolymerization in the presence of cupric sulphate ;5 A solution containing 2 mg/ml of heparin was incu bated in the presence of ascorbic acid 4 mM, cupric sulphate 0.5 mM, sodium chloride 0.5 M, sodium pho sphate 0.1 M at pH 7.8 for 24 hours at 40°C. ;The yield in oligosaccharides was 84% in weight 10 and the average molecular weight 9,260. ;The product resulted highly polluted, in practi cally irreversible manner, by cupric ions. ;b) Depolymerization in the presence of hydrogen peroxide ;15 The test described by Lasker was repeated accor ding to the alternative method suggested by the Lasker himself and consisting in substituting the cupric sulphate with a 3% solution of hydrogen peroxide. 0.5 m.moles of hydrogen peroxide/1 of solution 20 were used instead of 0.5 m.moles of cupric sulphate. The yield in weight was 90% and the average mo lecular weight was 11,700. ;c) Depolymerization in the presence of cupric sulphate and hydrogen peroxide ;25 The test was still repeated by using at the sa me time both the cupric sulphate and the hydrogen peroxide each of them in quantities of 0.5m.moles/1 of reaction mixture. ;The yield in weight was 94% and the average mole ;1 077 ;cular weight was 9,150. ;d) Depolymerization in the presence of cupric sulphate and hydrogen peroxide in a solution at a concentration 5 times higher than that of above 5 Example 5 c) ;A solution of 10 g of heparin per liter was incubated in the presence of 20 m.moles of ascorbic acid, 2.5 m.moles of cupric sulphate and 2.5 m.moles of hydrogen peroxide at 40°C for 20 hours. ;10 The pH was adjusted to 7.8 by means of 100 m.mo les of sodium phosphate Na^HPO . 2H 0. ;2 4 2 ;The solution contained also 500 m.moles of sodium chloride. The yield was 76% by weight and the average molecular weight was 10,936. ;15 e) Depolymerization in the presence of cupric sul- ;20 cular weight was 12,400. ;When considering the results obtained in the abo ve given examples it appears evident that for the process of the present invention the concentration of the solution in the reaction is unexpectedly a 25 critical factor both in order to obtain the desired average molecular weight and in order to obtain pro ducts having high ratios of antithrombotic activity/ anticoagulant activity. ;phate and hydrogen peroxide in a solution at a concentration 12.5 times higher than that of above Example 5 c) ;The yield was 76% by weight and the average mole ;On the other hand corresponding concentration ;- 12 - ;increases in the process derived from Lasker do not put into evidence any critic condition with reference both to the average molecular weight of the obtained oligosaccharide mixtures and to their biolo-5 gic properties. ;The average molecular weight was determined accor ding to J.C. Hilborn, and P.A. Inastassiadis: Anal. Biochemistry 3_9, 80-92 (1971). ;The anticoagulant activity was determined by 10 means of the method described by the United States ;Pharmacopoeia - pag. 298-300 - USP XX and by compari son with the International Standard of Heparin WHO III . ;TABLE 1 ;r.eparin ;In vitro ;I n ;Average molecular weight Dal tons ;U.l./USP Anticoagulant acti vi ty ;Anti-Xa coagulom. ;Anti-Xa cromo- ;genic ;APTT coag. Anti-Xa coag. ;(human pi.) (human pi.) ;Lipoprotein no i i p as i c acti vi ly ;APTT ;Heparin ;13500 ;139 ;170 ;135 ;105 ;124 . ;36 ;♦ ;8. ;,5 ;150 ;♦ ;6. ;,9 ;28.25 ;14.33 ;Ex. 1 ;4500 ;46 ;24, ;,53 ;49. ;.1 ;74 ;33. ;.64 ;+ ;3, ;.47 ;201. ;,47 ;+ ;17 ;.4 ;13 ;3.9 ;Ex. 2 ;3946 ;29.1 ;15. ;,2 ;33. ;,12 ;61, ;.43 ;14. ;,11 ;+ ;0, ;.06 ;137, ;.1 ;♦ ;6 ;.26 ;7 .77 ;1 .9 ;Ex. 3 ;5590 ;70. 7 ;59. ;,2 ;. 47, ;.6 ;73 ;39. ;.94 ;- ;0, ;.32 ;169. ;,77 ;+ ;8. ;.8 ;17 .12 ;5.29 ;Ex. 4 ;5986 ;63 ;35. ;, 74 ;54. ;,22 ;52. ;,97 ;34 . ;.59 ;0. ;.ao ;205, ;,9 ;16 ;12.02 ;3.1b ;Ex. 5 a ;9260 ;103.4 ;128. ;.1 ;77. ;.1 ;89 ;94 , ;,45 ;t- ;7, ;.5 ;122. ;,24 ;+ ;15 ;n. d. ;n.d. ;Ex. 5 b ;11700 ;126.2 ;165 ;111. ;.8 ;98 ;111 , ;. 19 ;1 ;2. ;.17 ;104 ;♦ ;7 ;n.d. ;n. a. ;Ex. 5 c ;9150 ;102.7 ;108 ;.2 ;74, ;.6 ;84 ;74. ;.59 ;t ;9, ;.03 ;121. ;.0 ;+ ;6, ;.4 ;n .a. ;n.d. ;Ex. 5 d ;10936 ;109 ;114, ;.9 ;90. ;.75 ;71 ;.49 ;75 ;.98 ;! ;2 ;.64 ;130, ;.18 ;♦ ;3 ;.49 ;n.d. ;n.d. ;Ex. 5 e ;12400 ;138 ;127 ;78. ;.82 ;103. ;.1 ;114 , ;, 47 ;1 ;5. ;.17 ;119, ;.17 ;— ;1, ;.87 ;n.d. ;n.d. ;n. d. = not determined ;(h i gh M. ) ;1—1 U> ;NJ O ;- 14 - ;2 077 ;For the anticoagulant activity, evaluated in vitro as partial activated thromboplastine time (APTT), the method of Basu D. et al., N. Eng. J. Med. 287, 1972, 324-27 was utilized. ;5 The Xa factor inhibiting activity was evaluated by means of the coagulometric method of Denson V.W.E., Bonnar J., Thromb. Diath. Haemorr. , 30, 1973, 471 or the cromogenic method of Teien A.N. et al., Thromb. Res., 8, 1976, 413. 10 The lipoproteinolipasic activity was evaluated by way of comparison with the House Standard by means of the method described by Bianchini P., 0s.i ma B., Casetta R. : Arterioscl. Journ. 5^, 1967 , 597 ; Bianchini P., Guidi G., Osima B.; Biochem. Exp. Biol. 15 10, 1972, 243. ;- Antithrombotic activity ;Although the Xa factor inhibiting activity i_n vi-tro is considered in certain limits related with the antithrombotic activity, it does not necessari-20 ly predict this one. ;Therefore a test was carried out relating to the inhibition of the thrombus formation in the rabbit, according to David J.L. et al. (C.R. Soc. Biol. 162, 1968, 1763-66), which is considered to be suitable 25 for the evaluation of the antithrombotic activity of a drug. ;The product obtained as described in example 1 proved to be effective when administered both intra venously and orally. ;2 07 7 ;- 15 - ;- Venous thrombosis from collagen. Antithrombotic effect of LMW Heparin administered i.v. in the rabbit. ;Treatment Dry weight mcg/kg of thrombus ;Inhibition ;0 5.65 + 0.31 0 ;500 4.19 + 0.47 25.84 ;1000 2.44+0.17 56.81 ;10 2000 1.72 + 0.29 69.56 ;- Venous thrombosis from collagen - antithrombotic activity of LMW Hep. and Standard Hep. i.v. ;15 determination of the ED values ;50 ;Treatment ED_ and conf. lim. ;50 ;USP un i t/kg i.v ;20 ;Ep. St. LMW ;102.52 (77.7 - 133.93) 47.72 (36.9 - 61.50) ;2 07793 ;- Venous thrombosis from collagen. Antithrombotic effect of LMW Hep. administered per os in the rabbit at the dose of 200 mg/kg. ;10 ;Treatment Unity Dry weight % Inhib. ;USP/kg of thrombus of the ;, 3 thrombus x 10 ;Control 0 5.94 + 0.82 — ;St. Hep. 30.3 6.12 + 0.65 0 ;LMW 9.8 3.17+0.39 48.2 ;In the following Table 2 the results are shown of chemical analysis carried out on starting He-15 parin and on some low molecular weight (LMW) oligosaccharide fractions obtained according to the process of the present invention. * TABLE 2 Champ.

U. A.

H . A.

S°3H~ < Electrophoretic test S-m% F-m% 4) Heparin 29 .33 29.64 28.45 42 50 50 Ex. 2 LMW Ex. 3 LMW Ex. 4 LMW 24.45 25.34 25 . 58 22 . 50 25.26 20. 95 .78 25 . 12 25 . 20 43 43 42 0 0 0 100 100 100 I 1) U.A. = Uronic Acids determined according to the method described by T. Bitter, H.

Muir, Biochem. Anal. £, 330-334, 1962. 2) H.A. = Hexosamines determined according to the method described by N. Boas, J. Biol.

Chem. 204, 533, 1953. 3) SO^H = Sulphates determined according to the method described by K.S. Dodyson, R.G.

Price, Biochem. J. 8_4 , 106, 1962. 4) S-m and F-m = Slow-moving and Fast-moving fractions. The electrophoresis is carried out according to the method described by P. Bianchini et al., J. Chro-matog. 19 6, 455-462, 1980.

N> O ~N] XI U 207793 r- PATENT Orf iCE -18 MAR 1986

Claims (4)

WHAT WE CLAIM IS: RECEIVED

1. Process for the preparation of oligosaccharide fractions provided with pharmacological properties, by means of heparin degradation, characterized by the fact that an aqueous heparin solution containing from 5 to 20 g of heparin per 1. is submitted to incubation in the presence of from 4 to 50 m.moles/1 of ascorbic acid, of from 0.4 to 2.5 m.moles/1 of cupric acetate, and of from 50 to 300 m.moles/1 of hydrogen peroxide at a temperature comprised between 40 and 50°C for 20-24 hours and maintaining the pH at a value comprised between 7.5 and 8 by means of sodium acetate.

2. Process according to claim 1 characterized by the fact that the process is carried out at a pH value of 7.8.

3. Process according to claim 1, characterized by the fact that the aqueous heparin solution con tains 10 g/1 of heparin, 20 m.moles/1 of ascorbic acid, 2.25 m.moles/1 of cupric acetate, and 180 m.moles/1 of hydrogen peroxide and by the fact that the process is carried out at a temperature of 50°C for 2.4 hours, keeping the pH at a value of 7.8 by means of sodium acetate.

4. Oligosaccharides fractions of heparin obtained by means of the process defined by any one of the preceding claims. WEST-WALKER, K'.cCADE per: ATTORNEYS FOR THE AFFLICANT